CD274 and Merkel cell skin cancer: On the basis of these results, immune checkpoint inhibition with PD-1/PD-L1 blockade is approved as first-line or subsequent-line treatment of MCC by the FDA (avelumab, pembrolizumab) and the European Medicine Agency (avelumab).